A pharmaceutical composition is disclosed comprising (-)-cis-2-methylspiro(1,3-oxathiolan-5,3')quinuclidine, and/or the pharmaceutically compatible acid addition salts thereof, together with at least one of physostigmine, tetrahydroaminoacridine, choline, lecithin, piracetam, aniracetam, pramiracetam, oxiracetam, 4-aminopyridine, 3,4-diaminopyridine, somatostatin, pirenzepine, N-methylatropine, N-butylscopolamine, scopolamine, clonidine, quanfamicine and Nerve Growth Factor. Also disclosed is a method for treating senile dementia of Alzheimer's type, which comprises coadministering to a patient in need thereof an effective dose of the spiro compound together with at least one other compound selected from those listed above.

State of Israel, represented by the Prime Minister's office, Israel

Pharmaceutical composition comprising a spiro oxathiolon/quinuclidine and method of treating senile dementia

Dehydroevodiamine-HCl, a constituent of Evodia rutaecarpa Benth. (DHED) exhibits anti-AChE activity and improves the memory impairment of animals produced by scopolamine in the passive avoidance test. Thus, DHED can be a potent, long term memory enhancing and anti-dementia agent if it is used together with a pharmaceutically acceptable carrier.

JE IL Pharmaceutical Co., Ltd.

Yoo-Hun Suh

Memory enhancing and anti-dementia agent containing dehydroevodiamine HC1 as active ingredient

Pharmaceutical compositions containing an extract of Houttuynia cordata (THUNB) as an active ingredient for preventing and treating dementia, Parkinson's disease, or epilepsy and methods for using the same. Since the extract of Houttuynia cordata or the mixture of the extract of Houttuynia cordata and the extract of Ampelopsis japonica Makino has a cell protection effect and/or a cognition function improved effect in various models including an Amyloid-.beta. induced dementia model, a scopolamine induced dementia model, a 6-hydroxydopamine (6-OHDA) induced Parkinson's disease model, and a Kainic acid induced epilepsy model, the extract of Houttuynia cordata or the mixture of the extract of Houttuynia cordata and the extract of Ampelopsis japonica Makino may be used as the pharmaceutical composition for preventing and treating dementia, Parkinson's disease, or epilepsy and in health foods for preventing and treating dementia, Parkinson's disease, or epilepsy.

UNIVERSITY INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY

UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY

Pharmaceutical composition containing extract of houttuynia cordata as active ingredient for preventing and treating dementia, parkinson's disease, or epilepsy

The use of extract form Wangla (coeloglossum viride (L) Hartm. Var. Bracteatum (Willd.) Richter), succinate derivative esters, and a derivative and pharmaceutical acceptable salts thereof, for the manufacture of a pharmaceutical preparation for the treatment of dementia, particularly for the treatment of Alzheimer' disease and Vascular dementia. Through Animal experiment, it has been demonstrated that, succinate derivative esters can improve learning and memory ability in dementia rats induced by scopolamine and cyclohexenyl imine; improve learning and memory ability in dementia rats induced by .beta.-amyloid; improve learning and memory ability in dementia rats induced by permanent ligation of bilateral carotid; and improve memory ability of normal animals. It has the advantage of high activity, low toxicity and no inhibition to cholinesterase.

dementia/escopolamina

Pharmaceutical composition comprising a spiro oxathiolon/quinuclidine and method of treating senile dementia

Memory enhancing and anti-dementia agent containing dehydroevodiamine HC1 as active ingredient

Pharmaceutical composition containing extract of houttuynia cordata as active ingredient for preventing and treating dementia, parkinson's disease, or epilepsy

Use of derivatives of succinate esters for the treatment of dementia

La base de dades d’herbes medicinals més completa avalada per la ciència